All In Biotech

Drug Trial Radar · NCT07480356

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-Grade Non-Muscle Invasive Bladder Cancer

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 284 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

284

Planned (sponsor's estimate)

Start

May 29, 2026

Primary completion

Apr 2028

Study completion Nov 2032

Sponsor

Lead sponsor
Protara TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if TARA-002 can treat high-grade non-muscle invasive bladder cancer (NMIBC) in BCG-naïve adults 18 years of age or older. The main questions it aims to answer are: * Can the study drug help participants with this type of cancer? * Is the study drug safe? * What are the side effects of the study drug? Researchers will compare TARA-002 to chemotherapy to see if TARA-002 works to treat NMIBC.

Conditions

  • Bladder (Urothelial, Transitional Cell) Cancer
  • Non-Muscle Invasive Bladder Carcinoma
  • Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Interventions

  • TARA-002Drug

    Participants will receive 6 weekly instillations of TARA-002. Participants confirmed to have a CR at Week 12 will enter the maintenance treatment period and will receive 3 additional weekly instillations of TARA-002 every 3 months up to Month 19, and then 3 weekly doses at Month 25. Participants who are eligible for reinduction at Week 12 will receive 6 additional weekly instillations of TARA-002. Participants who undergo reinduction and are confirmed to have a CR at Week 24 will enter the maintenance regimen treatment period and will receive 3 weekly instillations of TARA-002 every 3 months up to Month 19, and then 3 weekly doses at Month 25.

  • Investigator's Choice of Intravesical ChemotherapyDrug

    Participants will receive 6 weekly instillations of Investigator's choice of intravesical chemotherapy. Participants confirmed to have a CR at Week 12 will enter the maintenance regimen treatment period and will receive one intravesical instillation of Investigator's choice of intravesical chemotherapy every 1 month up to Month 25.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of high-grade complete responseTime frame: Month 6

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • East Valley Urology Center of Arizona

    Queen Creek, Arizona · Recruiting

  • Arkansas Urology

    Little Rock, Arkansas · Recruiting

  • Michael Oefelein Clinical Trials

    Bakersfield, California · Recruiting

  • Urology of Greater Atlanta - Sandy Springs

    Atlanta, Georgia · Recruiting

  • Renown Regional Medical Center

    St Louis, Missouri · Recruiting

  • START - Carolinas

    Myrtle Beach, South Carolina · Recruiting

  • Urology Partners of North Texas

    Arlington, Texas · Recruiting

  • Urology Austin, LLC

    Austin, Texas · Recruiting

  • Houston Metro Urology

    Houston, Texas · Recruiting

  • Arenia - Ivano-Frankivsk

    Ivano-Frankivsk, Ukraine · Recruiting

  • Arensia Kapitanivka - PPDS

    Kapitanivka, Ukraine · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.